Javier Urzay, deputy director of Farmaindustria, gives an overview of the growth of the pharmaceutical sector in Spain and the challenges to find a balance between rewarding innovation and sustainability. Moreover, he talks about the development of clinical trials in Spain and the currently discussed new collaboration agreement with the government.
Although it has been a complicated year because of all the changes in the government, we have managed to achieve good results
The Spanish Association of Orphan and Ultra Orphan Medicinal Products Laboratories (AELMHU) is a non-profit organisation working to improve awareness about rare diseases and access of Orphan Drugs. Maria Jose…
The executive president of Laboratorios Rubió, Carlos Rubió, analyses the fundamentals behind the Catalan company’s double-digit growth, its international expansion plan, which includes the United States, the doubling of capacity…
Maria Jose Sanchez Losada, general manager for CSL Behring Iberia, highlights the challenges that plasma-derived therapies faced during the COVID-19 pandemic, how the firm competes with well-established local players in…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
See our Cookie Privacy Policy Here